This phase 1 randomized, double blind placebo controlled study evaluated the effectiveness and safety of a specific type of sublingual CBD + THC liquid meant to be sprayed under the tongue (oromucosal). It was published in December 2022 in the Iranian Journal of Pharmaceutical Research.
The study included 50 patients, with an average age of about 54, who were treated daily for 8 weeks. 25 were given 2 sprays twice per day of CBDEX10® (1 spray = 100 µg cannabidiol (CBD) and 10 µg Δ9-tetrahydrocannabinol (THC)).
25 patients were given placebo sprays. These are VERY small total daily doses of about 0.4mg CBD and 0.04mg THC. To make this point, the authors reference another controlled trial and state: "most patients could tolerate up to 6000 mg/day of CBD". This certainly reinforces the cannabinoid dosing mantra: "Start LOW and Go SLOW". Why take MORE than you actually need? Starting low is the only way to really know what works best for YOU.
The study measured the effects of this specific dose on the lipid profile and glycemic state of the diabetic patients.
A statistically significant decline in total cholesterol, triglyceride, FBS and insulin secretion was observable in the patients treated with CBDEX10® at the end of the 8-week treatment period.
the plasma values recorded for T-CHOL, TG, and LDL-C in the treatment group were significantly lower [8.0%, 15.4%, and 4.7% respectively], than those observed in the control group after the eight-week treatment period (all P < 0.05)
values of HDL-C were not meaningfully changed in both groups at the end of the eight-week treatment period
there were no serious or severe adverse effects
these outcomes at the end of the eight-week treatment period represent the positive effects of the adjunctive regimen in controlling the lipid profile of patients with type II diabetes.
CBDEX1® sublingual spray could be a new therapeutic agent for lipid and glycemic control in diabetic patients.
The full text article is here at PubMed Central.